Werewolf Therapeutics, Inc. HOWL

HOWL Company Overview

Werewolf Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing conditionally activated biologic therapies designed to stimulate the immune system specifically within the tumor microenvironment. The company operates in the oncology and biopharmaceutical industries, with a core emphasis on next-generation immuno-oncology treatments that aim to improve efficacy while reducing systemic toxicity. Its primary revenue drivers to date are research and development activities, collaboration revenue, and funding from equity markets, as the company does not yet have approved commercial products.

The company’s strategy centers on its proprietary PREDATOR™ (Prodrug Activation Dependent On Tumor microenvironment) platform, which is designed to mask potent immune-stimulating payloads until they are selectively activated in tumors. Werewolf Therapeutics was founded in 2017 and completed its initial public offering in 2021, marking its transition to a publicly traded company. Since inception, it has evolved from a platform-focused startup into a clinical-stage organization advancing multiple candidates into human trials.